Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...

Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...

Elsewhere in the field, Ascletis Pharma’s once daily oral small molecule GLP-1RA has demonstrated a 6.3% cut in body weight after 28 days in a Phase Ib trial. Meanwhile, Novo Nordisk is planning a new ...

Novo Nordisk A/S, No. 25-cv-00713, alleges that the company and its key executives committed securities violations during the Phase 3 trial of CagriSema, known as REDEFINE-1. Investors who ...

Central to the lawsuit is the claim that the company's "optimistic forecasts" about CagriSema's effectiveness were unfounded. The suit also contends that the study's "flexible protocol," which ...

“The fourth quarter of 2024 was marked by two key announcements: the filing of patents covering, in particular, BioChaperone CagriSema—a stable combination of cagrilintide and semaglutide ...

CagriSema: Activating amylin and GLP-1 receptors CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials testing whether it can be ...

The company has grown its revenue by 18.58% over the last 5 years. NVO’s stock price fell after the CagriSema drug’s disappointing trial results. Despite strong earnings in the previous ...